Galectin Therapeutics, Inc. (NASDAQ: GALT) was founded in 2000, formerly known as Pro-Pharmaceuticals, Inc., changed to its current name in May 2011, headquartered in Norcross, Georgia, USA, with 7 full-time employees, and is a clinical Stage biopharmaceutical company engaged in research and development of fibrotic diseases and cancer treatments.
Galectin Therapeutics, Inc. (GALT):
Galectin Therapeutics is a biotechnology company focused on discovery and development. The company applies its leadership in galectin science and drug development to the creation of new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on Galectin Therapeutics’ unique carbohydrate technology target galectin proteins, which are key mediators of biological and pathological functions.
Galectin Therapeutics is looking for a variety of proven pathogenesis indications in which galectins are directly involved, such as a variety of inflammations, fibrosis and malignant diseases, and focuses on diseases that pose serious life threats to patients and currently lack treatment options. The company’s strategy is to establish a clinical development method, add value to the company in the shortest possible time, and seek partners as the program progresses, and more resources are needed.
Galectin Therapeutics’ lead product candidates include: galectin-3 inhibitor (GR-MD-02), which is used to treat liver fibrosis and cirrhosis and cancer in patients with non-alcoholic steatohepatitis Therapeutic galactose arabinose-rhamnose galacturonic acid polysaccharide polysaccharide polymer.
Galectin Therapeutics is also committed to the development of GM-CT-01 in preclinical development for the treatment of cardiac and vascular fibrosis, and is committed to the development of GR-MD-02 to treat psoriasis.
Galectin Therapeutics, Inc., through its joint venture Galectin Sciences, LLC with SBH Sciences, Inc., is engaged in the oral research and development of galectin-3 (galectin-3) small molecule organic molecular inhibitors.